Page last updated: 2024-10-24

positive regulation of plasma cell differentiation

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of plasma cell differentiation. [GOC:TermGenie]

Positive regulation of plasma cell differentiation is a complex biological process involving multiple signaling pathways and transcriptional factors. It is initiated by antigen recognition by B cells, leading to activation and differentiation into antibody-secreting plasma cells. The process is tightly regulated by a balance of positive and negative signals, ensuring efficient antibody production while preventing excessive inflammation and autoimmunity.

**1. Signal Transduction:**

* **B Cell Receptor (BCR) Signaling:** Antigen binding to the BCR triggers a cascade of intracellular signaling events, including activation of tyrosine kinases (e.g., Syk, Lyn), adaptor proteins (e.g., BLNK, SLP-65), and downstream signaling pathways like NF-κB and MAPK.

* **Cytokine Signaling:** Cytokines, such as IL-4, IL-6, and IL-10, produced by T helper cells (Th) and other immune cells, provide crucial signals for plasma cell differentiation. These cytokines activate specific signaling pathways, including STAT3, STAT6, and PI3K, leading to the upregulation of key transcription factors.

**2. Transcriptional Regulation:**

* **Transcription Factors:** Several transcription factors are essential for plasma cell differentiation. These include:
* **B lymphocyte-induced maturation protein 1 (BLIMP1):** A master regulator of plasma cell differentiation, BLIMP1 represses genes involved in B cell proliferation and promotes the expression of genes required for antibody production.
* **X-box binding protein 1 (XBP1):** A transcription factor involved in unfolded protein response, XBP1 promotes the expansion of the endoplasmic reticulum (ER), which is critical for antibody synthesis.
* **Pax5:** A key regulator of B cell development, Pax5 is downregulated during plasma cell differentiation, allowing the expression of plasma cell-specific genes.

* **Epigenetic Modifications:** Changes in DNA methylation and histone modifications play a crucial role in regulating gene expression during plasma cell differentiation. These modifications contribute to the stable silencing of genes involved in B cell development and the activation of genes required for antibody production.

**3. Antibody Production:**

* **Plasma Cell Maturation:** Differentiating plasma cells undergo significant morphological and functional changes, including increased ER size and accumulation of antibody molecules.
* **Antibody Secretion:** Plasma cells are highly specialized cells that efficiently produce and secrete large amounts of antibodies, which can neutralize pathogens and provide long-term immunity.

**4. Regulation and Feedback:**

* **Negative Feedback:** The production of antibodies can trigger negative feedback mechanisms that limit excessive plasma cell differentiation.
* **Immune Tolerance:** Tight regulation of plasma cell differentiation is crucial for maintaining immune tolerance and preventing autoimmunity.
* **Homeostasis:** The balance between plasma cell differentiation and apoptosis ensures proper antibody levels and prevents the accumulation of potentially harmful cells.'
"

Proteins (2)

ProteinDefinitionTaxonomy
Interleukin-2An interleukin-2 that is encoded in the genome of human. [PRO:CNA, UniProtKB:P60568]Homo sapiens (human)
Interleukin-10An interleukin-10 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P22301]Homo sapiens (human)

Compounds (8)

CompoundDefinitionClassesRoles
daidzindaidzein 7-O-beta-D-glucoside : A glycosyloxyisoflavone that is daidzein attached to a beta-D-glucopyranosyl residue at position 7 via a glycosidic linkage. It is used in the treatment of alcohol dependency (antidipsotropic).

daidzin: a potent, selective, and reversible inhibitor of human mitochondrial aldehyde dehydrogenase
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
plant metabolite
ononin4'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
monosaccharide derivative
plant metabolite
formononetin4'-methoxyisoflavones;
7-hydroxyisoflavones
phytoestrogen;
plant metabolite
luteolin-7-glucosideluteolin 7-O-beta-D-glucoside : A glycosyloxyflavone that is luteolin substituted by a beta-D-glucopyranosyl moiety at position 7 via a glycosidic linkage.

luteolin-7-glucoside: has both antiasthmatic and antineoplastic activities; has 3C protease inhibitory activity; isolated from Ligustrum lucidum
beta-D-glucoside;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone
antioxidant;
plant metabolite
N(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamideN(2)-carbamimidoyl-N-{2-[4-(3-{4-[(5-carboxyfuran-2-yl)methoxy]-2,3-dichlorophenyl}-1-methyl-1H-pyrazol-5-yl)piperidin-1-yl]-2-oxoethyl}-D-leucinamide : A leucine derivative obtained by fpormal condensation of the secondary amino group of 5-({2,3-dichloro-4-[1-methyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl]phenoxy}methyl)-2-furoic acid and the carboxy group of N-amidino-L-leucylglycineD-leucine derivative;
dichlorobenzene;
furoic acid;
glycine derivative;
guanidines;
pyrazolylpiperidine
calycosin-7-o-beta-d-glucopyranosidecalycosin-7-O-beta-D-glucoside : A glycosyloxyisoflavone that is calycosin substituted by a beta-D-glucopyranosyl residue at position at 7 via a glycosidic linkage.

calycosin-7-O-beta-D-glucoside: from Radix Astragali
4'-methoxyisoflavones;
7-hydroxyisoflavones 7-O-beta-D-glucoside;
hydroxyisoflavone;
monosaccharide derivative
diosgenin glucosidediosgenin 3-O-beta-D-glucoside : A sterol 3-beta-D-glucoside having diosgenin as the sterol component.

diosgenin glucoside: RN given refers to (3beta,25R)-isomer; structure given in first source
hexacyclic triterpenoid;
monosaccharide derivative;
spiroketal;
sterol 3-beta-D-glucoside
metabolite
hg-9-91-01HG-9-91-01 : A member of the class of phenylureas that is a potent inhibitor of salt-inducible kinase 2, a potential target protein for therapy in ovarian cancer.

HG-9-91-01: inhibits salt-inducible kinases; structure in first source
aminopyrimidine;
dimethoxybenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas;
secondary amino compound
antineoplastic agent;
salt-inducible kinase 2 inhibitor